Start-up company, Rocket Pharmaceuticals, has agreed to reverse merge with troubled Inotek Pharmaceuticals to advance its pipeline of first-in-class gene therapies to treat rare diseases. The combined company will retain the Rocket Pharmaceuticals name and will focus on advancing Rocket’s lentiviral virus (LVV) and adeno-associated virus (AAV) gene therapy platforms to treat rare disorders, such as Fanconianaemia, leukocyte adhesion deficiency-1 and pyruvate kinase deficiency. Rocket plans to move one or more of its programmes into clinical testing in 2018.